Anika Therapeutics | ANIK - Debt


Anika Therapeutics reported $0 in Debt for its fiscal quarter ending in March of 2025.





Debt Change Date
Abbott USD 13.86B 919M Dec/2025
Agenus USD 35.54M 2.34M Mar/2025
Agios Pharmaceuticals USD 40.21M 4.31M Dec/2025
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 312.77M 53.52M Dec/2025
Enanta Pharmaceuticals USD 1.35M 0 Dec/2024
Halozyme Therapeutics USD 2.14B 2.01M Mar/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Insmed USD 727.62M 275K Mar/2026
Integra LifeSciences USD 2.04B 6.27M Mar/2026
Intrexon USD 0 13.82M Jun/2024
J&J USD 47.93B 2.14B Dec/2025
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Ligand Pharmaceuticals USD 451.49M 494K Dec/2025
MacroGenics USD 36.51M 500K Mar/2026
Merit Medical Systems USD 821.57M 420K Dec/2025
Rigel Pharmaceuticals USD 59.69M 90K Jun/2024
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 20.33B 1.43B Dec/2025
Smith & Nephew USD 3.32B 334M Dec/2024
Stryker USD 14.22B 635M Mar/2026
Veracyte USD 39.65M 799K Dec/2025
Xencor USD 187.75M 118.48M Dec/2025
Zimmer Biomet Holdings USD 7.47B 48.1M Mar/2026